Please login to the form below

Not currently logged in
Email:
Password:

Scott Whitcup joins Questcor’s board of directors

Allergan’s chief scientific officer to help expand Acthar’s use to treat autoimmune conditions

Scott Whitcup - Questcor PharmaceuticalsScott Whitcup, executive VP of R&D and chief scientific officer at Amgen, has joined the board of directors at Questcor Pharmaceuticals.

The company said his experience in commericialising Botox as a treatment for chronic migraine, upper limb spasticity and neurogenic urologic conditions would be beneficial in Questcor's efforts to expand the uses of its own Acthar Gel brand to treat autoimmune conditions.

“The growth strategies and product manufacturing for Acthar and Botox have some interesting parallels,” said Questcor's chair, Virgil Thompson.

Acthar is currently approved in the US in several indications, including infantile spasms; exacerbations of multiple sclerosis in adults; nephrotic syndrome; and several rheumatic disorders including collagen diseases; dermatologic diseases and ophthalmic diseases.

Whitcup joined Allergan in 2000, becoming executive VP of R&D in 2004 and chief scientific officer in 2009.

Other products he has helped bring to market at Allergan include Lumigan, Restasis and Latisse.

Prior to joining Allergan Whitcup served as clinical director at the National Institutes of Health's National Eye Institute, where he help develop new therapies for ophthalmic diseases

22nd February 2012

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare focused, award-winning video production company which operates in the US and Europe....

Latest intelligence

Finding the patient voice
How patients feel and speak about clinical trials...
Six Factors to Consider When Designing Advisory Boards
...
The good, the bad and the ugly
Tracking the pharmaceutical industry’s 2017 evolution and assessing how things may shape up in 2018 - it’s a trilogy of trends...

Infographics